Menu
Back to User profile » Prof. Dr. Andreas Doesch
Papers published by Prof. Dr. Andreas Doesch:
COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Darche FF, Thomas D, Bruckner T, Katus HA, Ehlermann P, Doesch AO
Clinical Epidemiology 2018, 10:1359-1369
Published Date: 27 September 2018
Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality
Rivinius R, Helmschrott M, Ruhparwar A, Rahm AK, Darche FF, Thomas D, Bruckner T, Ehlermann P, Katus HA, Doesch AO
Therapeutics and Clinical Risk Management 2017, 13:1399-1407
Published Date: 13 October 2017
Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2017, 11:1827-1837
Published Date: 19 June 2017
Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy
Helmschrott M, Rivinius R, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2017, 11:1673-1680
Published Date: 7 June 2017
The influence of surgical technique on early posttransplant atrial fibrillation — comparison of biatrial, bicaval, and total orthotopic heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Erbel C, Gleissner CA, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO
Therapeutics and Clinical Risk Management 2017, 13:287-297
Published Date: 8 March 2017
Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2016, 10:677-686
Published Date: 16 February 2016
Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation
Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2015, 9:1217-1224
Published Date: 24 February 2015
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2015, 9:93-102
Published Date: 17 December 2014
CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions
Akhavanpoor M, Gleissner CA, Gorbatsch S, Doesch AO, Akhavanpoor H, Wangler S, Jahn F, Lasitschka F, Katus HA, Erbel C
Drug Design, Development and Therapy 2014, 8:2359-2371
Published Date: 27 November 2014
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen
Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2014, 8:1307-1314
Published Date: 9 September 2014
Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions
Doesch AO, Zhao L, Gleissner CA, Akhavanpoor M, Rohde D, Okuyucu D, Hakimi M, Dengler TJ, Katus HA, Erbel C
Drug Design, Development and Therapy 2014, 8:447-457
Published Date: 12 May 2014
Conversion to generic cyclosporine A in stable chronic patients after heart transplantation
Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, Ruhparwar A, Ehlermann P, Katus HA, Doesch AO
Drug Design, Development and Therapy 2013, 7:1421-1426
Published Date: 28 November 2013
Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study
Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA
Drug Design, Development and Therapy 2013, 7:1323-1328
Published Date: 5 November 2013
Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation
Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA
Drug Design, Development and Therapy 2013, 7:1253-1258
Published Date: 21 October 2013
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation
Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO
Drug Design, Development and Therapy 2013, 7:297-303
Published Date: 8 April 2013
Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA
Drug Design, Development and Therapy 2012, 6:289-295
Published Date: 12 October 2012